| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2013-05-27 | Medigene (Germany) SynCore Biotechnology (Taiwan) | EndoTAG®-1 | triple-negative breast cancer (TNB, pancreatic cancer | co-development |
Cancer - Oncology | Development agreement |
| 2013-05-23 | Agilent Technologies (USA) University of Rouen (France) A*STAR’S Bioprocessing Technology Institute (Singapore) | tools to effectively analyze biologics and vaccines | R&D |
Technology - Services | R&D agreement | |
| 2013-05-23 | Cenix BioScience (USA) Debiopharm (Switzerland) | predictive biomarkers | R&D |
Cancer - Oncology | R&D agreement | |
| 2013-05-23 | Roche (Switzerland) Macrocyclics (an AREVA Med company) (USA) | novel chelating agents | R&D |
Cancer - Oncology | R&D agreement | |
| 2013-05-23 | IMI (EU) Critical Path Institute (USA) | drug safety tests | collaboration |
Technology - Services | Collaboration agreement | |
| 2013-05-22 | GSK (UK) Department of Health and Human Services (HHS) (USA) | antibiotics | development |
Infectious diseases | Development agreement | |
| 2013-05-21 | The Cell Therapy Catapult (UK) GSK (UK) | cell therapies | R&D |
Regenerative medicine | R&D agreement | |
| 2013-05-21 | Grifols (Spain) Aradigm Corporation (USA) | proprietary formulations of inhaled ciprofloxacin (Pulmaquin and Lipoquin™) | severe respiratory diseases, including non-cystic fibrosis bronchiectasis | licensing |
Respiratory diseases | Licensing agreement |
| 2013-05-21 | QuantuMDx (UK) Genome Institute of Singapore (Singapore) | point-of-care genetic tests | development |
Diagnostic - Cancer - Oncology | Development agreement | |
| 2013-05-20 | Epistem (UK) ScandiDerma (Norway) | n vitro human living skin equivalent model for testing inflammatory responses | Technology - Services | Services contract | ||
| 2013-05-16 | Evotec (Germany) Harvard University (USA) | novel anti-bacterial agents targeting peptidoglycan biosynthesis | R&D |
Infectious diseases | R&D agreement | |
| 2013-05-15 | Merck Serono (Germany) Quintiles (USA) | clinical development programs | clinical research |
Cancer - Oncology - Neurological diseases - Immunological diseases | Clinical research agreement | |
| 2013-05-15 | Roche (Switzerland) Curie Cancer (France) The Roche Institute for Research and Translational Medicine | translational research programs | R&D |
Cancer - Oncology | Clinical research agreement | |
| 2013-05-14 | CMC Biologics (Denmark) RuiYi (China) | RYI-008 | development |
Development agreement | ||
| 2013-05-14 | Cobra Biologics (Sweden) Vaccibody (Norway) | DNA vaccine candidate against HPV-induced malignancies | HPV-induced malignancies such as precancerous lesions found in cervical cancer | manufacturing |
Cancer - Oncology - Infectious diseases | Production agreement |
| 2013-05-14 | Calypso Biotech (Switzerland) iDD Biotech (France) | potential first in class monoclonal antibody | refractory celiac disease | licensing | Autoimmune diseases | Licensing agreement |
| 2013-05-13 | Elan (Ireland) Theravance (USA) | participation interest in potential future royalty payments related to four respiratory programs partnered with GSK: Relvar™ Ellipta™/Breo™ Ellipta™, Anoro™ Ellipta™, MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist) monotherapy (GSK961081, or MABA \'081), and vilanterol (VI) monotherapy | collaboration |
Respiratory diseases | Collaboration agreement | |
| 2013-05-13 | Vectura (UK) Tianjin KingYork Group (China) Zendex Bio Strategy | Kinnovata Pharmaceutical | joint-venture |
Respiratory diseases | Joint-venture agreement | |
| 2013-05-09 | Baliopharm (Switzerland) ApoGbR (Germany) | Novotarg | specific lymphomas, B-cell mediated inflammatory diseases | licensing |
Cancer - Oncology - Inflammatory diseases | Licensing agreement |
| 2013-05-08 | Shire (UK) Nimbus Discovery (USA) | first-in-class small molecule treatments | lysosomal storage disorders | R&D |
Rare diseases - Genetic diseases | R&D agreement |
